Clinical outcomes of early-stage breast cancer in Morocco: A cohort of 400 women

Table 1 Demographics and tumor characteristics in women with early breast cancer in Morocco (n = 400)

Characteristic	Patients (n)	%
Age (years)
< 40	119	30.0
40-50	176	44.0
> 50	105	26.0
Menopausal status
No	263	66.0
Yes	137	34.0
Tumor side
Right breast	194	48.5
Left breast	205	51.0
Bilateral	1	0.5
Histology
IDC	367	92.0
ILC	25	6.0
Others	8	2.0
Grade (SBR)
I	27	6.7
II	250	62.5
III	112	28.0
Missing	11	2.8
Hormone receptor
Positive	398	73.0
Negative	100	25.0
Missing	2	0.5
Tumor stage (pT)
T1	49	12.2
T2	226	56.5
T3	98	24.5
T4	19	4.8
Missing	8	2.0
Axillary status (pN)
N0	96	24.0
N+	301	75.0
N1	114	28.5
N2	124	31.0
N3	63	15.5
Missing	3	1.0
AJCC stage
I	8	2.0
II	161	40.2
III	216	54.0
Missing	15	3.8

AJCC: American Joint Committee on Cancer; HR: Hormone receptor; IDC: Invasive ductal carcinoma; ILC: Invasive lobular carcinoma; SBR: Scarff-Bloom-Richardson.

Table 2 Treatments used in women with early-stage breast cancer in Morocco (n = 400)

Treatment	Patients (n)	%
Surgery
Mastectomy	344	86.0
Breast-conserving surgery	56	14.0
Chemotherapy
Anthracycline-based regimen	249	62.2
CMF regimen	151	37.8
Radiotherapy - breast/thoracic wall
Breast	56	14.0
Thoracic wall	344	86.0
Radiotherapy - lymph nodes
Supraclavicular ± IMC	333	83.2
Axillary	60	15.0

BCT: Breast-conserving surgery; CMF: Cyclophosphamide, methotrexate, fluorouracil; IMC: Internal mammary chain.

Table 3 Survival outcomes of patients in patients with early breast cancer in Morocco

Survival	At 1-year (95%CI)	At 3-year (95%CI)	At 5-year (95%CI)
OS	99% (98%-100%)	91.4% (88.6%-94.4%)	82.1% (78.1%-86.3%)
DFS	98.5% (97.3%-99.7%)	85.4% (81.9%-89.1%)	78.1% (73.8%-82.6%)
LRRFS	99.7% (99.2%-100%)	96.9% (95.1%-98.7%)	96.5% (96.4%-98.5%)

CI: Confidence interval; DFS: Disease-free survival; LRRFS: Locoregional recurrence-free survival; OS: Overall survival.

Table 4 Univariate and multivariate analyses of prognostic factors on overall survival in women with early-stage breast cancer (n = 400)

Factors		Participants	Hazard ratio (univariable)	Hazard ratio (multivariable)
Age (year)	≥ 40	282 (75.2)	-	-
	< 40	93 (24.8)	0.96 (0.56-1.67, P = 0.897)	1.15 (0.65-2.02, P = 0.636)
Grade (SBR)	1-2	268 (71.5)	-	-
	3	107 (28.5)	1.48 (0.90-2.44, P = 0.121)	1.44 (0.85-2.43, P = 0.171)
Histology	IDC	355 (94.7)	-	-
	ILC	20 (5.3)	1.48 (0.59-3.68, P = 0.401)	1.77 (0.69-4.54, P = 0.237)
Hormone receptor	HR-	94 (25.1)	-	-
	HR+	281 (74.9)	0.89 (0.52-1.51, P = 0.660)	0.97 (0.56-1.67, P = 0.903)
pT	pT2-3	111 (29.6)	-	-
	pT1-2	264 (70.4)	0.64 (0.39-1.04, P = 0.071)	1.00 (0.59-1.72, P = 0.988)
pN	pN+	288 (76.8)	-	-
	pN0	87 (23.2)	0.34 (0.16-0.75, P = 0.007)	0.70 (0.27-1.82, P = 0.469)
Stage	3	208 (55.5)	-	-
	1-2	167 (44.5)	0.29 (0.16-0.52, P < 0.001)	0.32 (0.15-0.67, P = 0.002)
Treatment	CMF	142 (37.9)	-	-
	Anthra	233 (62.1)	0.67 (0.42-1.08, P = 0.098)	0.58 (0.35-0.94, P = 0.027)

CMF: Cyclophosphamide, methotrexate, fluorouracil; HR: Hormone receptor; IDC: Invasive ductal carcinoma; ILC: Invasive lobular carcinoma; pT: Pathological tumor stage; pN: Pathological lymph node stage; SBR: Scarf-Bloom-Richardson.

Table 5 Univariate and multivariate analyses of prognostic factors on disease-free survival in women with early-stage breast cancer (n = 400)

Factors		Participants	Hazard ratio (univariable)	Hazard ratio (multivariable)
Age (year)	≥ 40	282 (75.2)	-	-
	< 40	93 (24.8)	1.01 (0.62-1.66, P = 0.964)	1.18 (0.71-1.96, P = 0.530)
Grade (SBR)	1-2	268 (71.5)	-	-
	3	107 (28.5)	1.28 (0.80-2.04, P = 0.301)	1.15 (0.71-1.88, P = 0.563)
Histology	IDC	355 (94.7)	-	-
	ILC	20 (5.3)	1.25 (0.50-3.08, P = 0.632)	1.27 (0.50-3.21, P = 0.611)
Hormone receptor	HR-	94 (25.1)	-	-
	HR+	281 (74.9)	0.76 (0.48-1.22, P = 0.262)	0.80 (0.49-1.31, P = 0.378)
pT	pT2-3	111 (29.6)	-	-
	pT1-2	264 (70.4)	0.56 (0.36-0.88, P = 0.012)	0.76 (0.46-1.25, P = 0.285)
pN	pN+	288 (76.8)	-	-
	pN0	87 (23.2)	0.46 (0.24-0.86, P = 0.016)	0.66 (0.30-1.44, P = 0.298)
Stage	Stage 3	208 (55.5)	-	-
	Stage 1-2	167 (44.5)	0.41 (0.25-0.67, P < 0.001)	0.51 (0.27-0.97, P = 0.041)
Treatment	CMF	142 (37.9)	-	-
	Anthra	233 (62.1)	0.63 (0.41-0.98, P = 0.040)	0.56 (0.36-0.86, P = 0.009)

CMF: Cyclophosphamide, methotrexate, fluorouracil; HR: Hormone receptor; IDC: Invasive ductal carcinoma; ILC: Invasive lobular carcinoma; pT: Pathological tumor stage; pN: Pathological lymph node stage; SBR: Scarf-Bloom-Richardson.